Dr Reddy has partnered with Alvotech to Manufacture Cancer Immunotherapy

A major collaboration between Indian-origin global pharmaceutical company Dr Reddy’s Laboratories has signed an agreement with Alvotech. According to the signed agreement, this partnership will develop, manufacture and commercialize pembrolizumab, a biosimilar candidate to Keytruda for global markets.

• Global pharmaceutical company Dr Reddy has partnered with Iceland’s Alvotech
• This partnership will be manufacturing pembrolizum immunotherapy for cancer
• Both companies will have equal responsibilities with development, responsibilities over manufacturing.

According to the signed agreement, the partnered companies will jointly share the responsibilities related to development, manufacturing costs and responsibilities of manufacturing. Both companies will have global commercialization rights with few exceptions. These frameworks of the agreement have allowed the companies to increase their global expansion.

Keytruda is an immunotherapy drug that has played a major role in treating numerous cancer types. CEO of Dr Reddy’s, Erez Israeli said, “This collaboration demonstrates our ability to develop high-quality, affordable treatment options for patients worldwide while enhancing their oncology capabilities.” This partnership highlights the company’s entry into oncology. Chairman and CEO of Alvotech, Róbert Wessman said, “This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline.”

Keytruda has generated USD 29.5 billion in worldwide sales in 2024. Hence, this partnership is expected to become one of the world’s largest cancer treatment markets.